Peter M. Ellis

Peter M. Ellis

Auto-generated profile, based on publicly available information

Peter M. Ellis

Department of Psychological Medicine, University of Otago, Wellington, New Zealand

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
KSKate M. Scott
Kate M. Scott
DSDon R. Smith
Don R. Smith
PEPete M. Ellis
Pete M. Ellis
Although child maltreatment (abuse and neglect) is only one of a number of childhood adversities that are associated with psychopathology,1-3 it is perhaps the most controversial of such associations. The evidence for this association heavily relies on retrospective reports of past abuse,4-9 and doubts have been raised about the reliability and validity of these reports given the substantial nonreporting of past maltreatment10,11; the possibility that the mental disorder outcomes under study may bias reporting of abuse via mood-congruent recall12; evidence that autobiographical memory can be subject to reconstruction13; and the possible instability of retrospective reports over time.14,15

1 June 2012 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
KSKate M. Scott
Kate M. Scott
KMKatie A. McLaughlin
Katie A. McLaughlin
DSDon A. R. Smith
Don A. R. Smith
PEPete M. Ellis
Pete M. Ellis
Background: Prior research reports stronger associations between childhood maltreatment and adult psychopathology when maltreatment is assessed retrospectively compared with prospectively, casting doubt on the mental health risk conferred by maltreatment and on the validity of retrospective reports.Aims: To investigate associations of psychopathology with prospectivev.retrospective maltreatment ascertainment.Method: A nationally representative sample of respondents aged 16–27 years (n= 1413) in New Zealand completed a retrospective assessment of maltreatment and DSM-IV mental disorders. Survey data were linked with a national child protection database to identify respondents with maltreatment records (prospective ascertainment).Results: Childhood maltreatment was associated with elevated odds of mood, anxiety and drug disorders (odds ratios = 2.1–4.1), with no difference in association strength between prospective and retrospective groups. Prospectively ascertained maltreatment predicted unfavourable depression course involving early onset, chronicity and impairment.Conclusions: Prospectively and retrospectively assessed maltreatment elevated the risk of psychopathology to a similar degree. Prospectively ascertained maltreatment predicted a more unfavourable depression course.

15 May 2008 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
SPSusanna E. Palmer
Susanna E. Palmer
RMRachael M. McLean
Rachael M. McLean
PEPeter M. Ellis
Peter M. Ellis
MHMira Harrison-Woolrych
Mira Harrison-Woolrych
To raise awareness of potentially lethal clozapine-induced gastrointestinal hypomotility (CIGH) by reviewing cases from the literature and unpublished pharmacovigilance data and to offer strategies aimed at prevention and early treatment. Databases (PsycINFO, 1967-2007; MEDLINE, 1950-2007; and EMBASE, 1988-2007) were searched using the term clozapine together with each of the following: gastrointestinal, dysmotility, constipation, obstipation, fecal impaction, fecaloma, paralytic ileus, adynamic ileus, subileus, ischemic colitis, colon ischemia, bowel ischemia, gastrointestinal ischemia, gut ischemia, obstruction, necrosis, gangrene, bowel perforation, micro-perforation, megacolon, toxic megacolon, acquired megacolon, pseudo-obstruction, Ogilvie, and Ogilvie's syndrome. We analyzed the electronic database entries held by the Adverse Drug Reactions Advisory Committee and the New Zealand Intensive Medicines Monitoring Program, which cited suspected clozapine-related gastrointestinal side effects, as well as all relevant published case reports. We reviewed the literature on the treatment of gastrointestinal hypomotility and constipation. We compiled a database of 102 cases of suspected life-threatening CIGH. There was a mortality rate of 27.5% and considerable morbidity, largely due to bowel resection. Within Australasia, at least 15 patients have died of CIGH. Probable risk factors are identified as recent instigation of clozapine, high clozapine dose or serum level, concomitant anticholinergic use, or intercurrent illness. The paucity of literature on CIGH suggests that the significance of this uncommon but important and frequently fatal side effect has not been recognized. Clozapine can affect the entire gastrointestinal system, from esophagus to rectum, and may cause bowel obstruction, ischemia, perforation, and aspiration. The mechanism is likely to be anticholinergic and antiserotonergic. Clozapine prescribing should be accompanied by regular physical monitoring, appropriate and timely use of laxatives, and early referral of constipated patients--before life-threatening pathologic processes develop.

15 July 2010 in Medical Education
Verified
Journal Article
Closed access
PDF file
JMJoanna MacDonald
Joanna MacDonald
SSSangsu Sohn
Sangsu Sohn
PEPete Ellis
Pete Ellis

12 August 2009 in Nephron Clinical Practice
Verified
Journal Article
Closed access
PDF file
NTNihad A.M. Tamimi
Nihad A.M. Tamimi
PEPeter Ellis
Peter Ellis
Drug development is an expensive, long and high-risk business taking 10–15 years and is associated with a high attrition rate. It is driven by medical need, disease prevalence and the likelihood of success. Drug candidate selection is an iterative process between chemistry and biology, refining the molecular properties until a compound suitable for advancing to man is found. Typically, about one in a thousand synthesised compounds is ever selected for progression to the clinic. Prior to administration to humans, the pharmacology and biochemistry of the drug is established using an extensive range of in vitro and in vivo test procedures. It is also a regulatory requirement that the drug is administered to animals to assess its safety. Later-stage animal testing is also required to assess carcinogenicity and effects on the reproductive system. Clinical phases of drug development include phase I in healthy volunteers to assess primarily pharmacokinetics, safety and toleration, phase II in a cohort of patients with the target disease to establish efficacy and dose-response relationship and large-scale phase III studies to confirm safety and efficacy. Experience tells us that approximately only 1 in 10 drugs that start the clinical phase will make it to the market. Each drug must demonstrate safety and efficacy in the intended patient population and its benefits must outweigh its risks before it will be approved by the regulatory agencies. Strict regulatory standards govern the conduct of pre-clinical and clinical trials as well as the manufacturing of pharmaceutical products. The assessment of the new medicinal product’s safety continues beyond the initial drug approval through post-marketing monitoring of adverse events.

1 March 2016 in EBioMedicine
Verified
Journal Article
Open access
SESusanna Every-Palmer
Susanna Every-Palmer
MNMike Nowitz
Mike Nowitz
JSJames Stanley
James Stanley
EGEve Grant
Eve Grant
MHMark Huthwaite
Mark Huthwaite
PEPete M. Ellis
Pete M. Ellis
Gastrointestinal side effects are particularly common with clozapine and occur with other antipsychotics, ranging from mild constipation to fatal bowel obstruction and/or ischemia. While this adverse-effect spectrum has been attributed to 'gastrointestinal hypomotility', gastrointestinal transit times in antipsychotic-treated patients have not previously been measured, making this mechanism speculative. Using standardized radiopaque marker ('Metcalf') methods we established colonic transit times of antipsychotic-treated psychiatric inpatients and compared them with population normative values. We analyzed results by antipsychotic type, antipsychotic dose equivalent, anticholinergic load, duration of treatment, gender, ethnicity, and age. For patients not prescribed clozapine, median colonic transit time was 23 h. For patients prescribed clozapine, median transit time was 104.5 h, over four times longer than those on other antipsychotics or normative values (p < 0.0001). Eighty percent of clozapine-treated patients had colonic hypomotility, compared with none of those prescribed other antipsychotics (olanzapine, risperidone, paliperidone aripiprazole, zuclopenthixol or haloperidol). In the clozapine group, right colon, left colon and rectosigmoid transit times were all markedly abnormal suggesting pan-colonic pathology. Hypomotility occurred irrespective of gender, age, ethnicity, or length of clozapine treatment. Transit times were positively correlated with clozapine plasma level (rho = 0.451, p = 0.045), but not with duration of treatment, total antipsychotic load or demographic factors. Clozapine, unlike the other antipsychotics examined, causes marked gastrointestinal hypomotility, as previously hypothesized. Pre-emptive laxative treatment is recommended when starting clozapine.